CMB International: Raised Li-Sanch Pharmaceutical (01530.HK) target price to HKD 37.67, maintains "Buy" rating.

According to the Wisdom Financial APP, CMB International released a research report stating that SanSan Pharmaceutical (01530.HK) and Pfizer's global (excluding China) licensing agreement for 707 (PD-1/VEGF dual antibody) has officially taken effect. It maintains a "buy" rating, with a target price raised from 28.32 Hong Kong dollars to 37.67 Hong Kong dollars.